Dr. Najam A. Sharif is a graduate of Southampton University, England (UK), where he received his BSc (Joint Honors: Biochemistry and Physiology) and his PhD (Neuroscience). During his 22-year tenure at Alcon, Dr. Sharif has contributed to the discovery, development, and US FDA approvals of Travatan®, Patanol®, Simbrinza®, Izba®, and Pazeo® to treat glaucoma, ocular hypertension, and ocular allergies. Dr. Sharif is an editor, associate editor, and editorial board member of many pharmacology and ophthalmic journals. He is the recipient of the inaugural Dr. Roger Vogel Award for Ocular Pharmaceutical Research (ARVO Foundation, 2104), the recipient of the Sir James Black Award for contributions to drug discovery (BPS, 2017), and the recipient of the Ernst Barany Prize for outstanding contributions to ocular pharmacology. Dr. Sharif is an adjunct professor, honorary senior lecturer, senior principal investigator, and graduate faculty member at multiple universities worldwide. He has also been a PhD candidate supervisor, advisor, and mentor to several students at numerous academic institutions. Dr. Sharif has published >215 scientific articles, edited 3 books, holds 24 issued US/EU patents, and has filed >30 patent applications over the last two decades. His research interests include ocular function and disease, prostanoid release, ocular hypertension, glaucoma, ocular allergies, neuroprotection, receptor pharmacology, and drug discovery and development.
